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Abstract
Background: Cognitive composite scores are used as the primary outcome measures for Alzheimer’s disease (AD)
prevention trials; however, the extent to which these composite measures correlate with AD pathology has not
been fully investigated. Since many on-going AD prevention studies are testing therapies that target either amyloid
or tau, we sought to establish an association between a cognitive composite score and the underlying pathology
of AD.
Methods: Data from 192 older deceased and autopsied persons from the Rush Religious Order Study were used in
this study. All participants were classified at their initial evaluations with a clinical diagnosis of no cognitive impairment
(NCI). Of these individuals, 105 remained NCI at the time of their death while the remaining 87 progressed to mild
cognitive impairment (MCI) or AD. A cognitive composite score composed of eight cognitive tests was used as the
outcome measure. Individuals were classified into groups based on Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) neuropathological diagnosis and Braak stage.
Results: The rate of annualized composite score decline was significantly greater for the high CERAD (p < 0.001, d = 0.56)
and Braak (p < 0.001, d = 0.55) groups compared with the low CERAD and Braak groups, respectively. Mixed-model
repeated measure (MMRM) analyses revealed a significantly greater difference in composite score change from baseline
for the high CERAD group relative to the low CERAD group after 5 years (Δ = −2.74, 95% confidence interval (CI) −5.01
to −0.47; p = 0.02). A similar analysis between low and high Braak stage groups found no significant difference in change
from baseline (Δ = −0.69, 95% CI −3.03 to 1.66; p = 0.56).
Conclusions: These data provide evidence that decreased cognitive composite scores were significantly associated with
increased AD pathology and provide support for the use of cognitive composite scores in AD prevention trials.
Keywords: Amyloid, Tau, Cognition, Prevention, Pre-clinical, Neuropathology

Background
The recent initiation of secondary prevention trials for
Alzheimer’s disease (AD) [1, 2] has resulted in a paradigm
shift in the AD clinical research field, with the focus on
identifying individuals who are at risk of developing AD
by virtue of age, genetic risk factors, and/or the presence
of AD pathology through neuroimaging technologies.
Until more robust associations between clinical outcomes
and neuroimaging/fluid-based biomarkers are established
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[3], the gold standard measure of efficacy in AD clinical
prevention trials will continue to be the clinical evaluation
of cognitive changes over time. However, the cognitive assessments in AD clinical trials are not sensitive enough to
detect changes in less cognitively impaired individuals [4,
5], and therefore their use in prevention trials remains dubious. To identify the earliest clinically meaningful
changes in cognition, the use of a composite score comprised of several different cognitive tests has been proposed [6]. Given that the incidence of mild cognitive
impairment (MCI) can vary greatly [7, 8], AD prevention
trials that use time-to-event as an outcome require extended observation periods to accurately assess disease
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progression. As a result, it is important that prevention
trials use measures of cognition that can demonstrate
meaningful treatment effects in the preclinical stages of
dementia with reasonable trial durations.
It has been suggested that preclinical AD can be characterized by subtle cognitive changes that are detectable
via sensitive neuropsychological tests and reflect the initial stages of the disease process [9, 10]. In addition, preclinical AD is also characterized by a lack of functional
decline [11], which puts greater significance on the ability to demonstrate treatment efficacy through cognitive
assessments in AD prevention trials. Therefore, emphasis has been directed towards the creation and validation of cognitive composite scores as primary efficacy
measures in AD prevention trials to detect subtle cognitive changes between treatment and placebo groups.
Several different cognitive composite measures have
been developed [12–16] which are sensitive to subtle
cognitive decline during the preclinical phase of AD.
These composite scores were developed in different populations using differing variables (e.g., APOE ɛ4 status,
amyloid positivity, postmortem AD neuropathology) to
differentiate preclinical AD from age-similar controls.
Others have proposed the Catch-Cog, a composite score
that combines information from performance-based cognitive assessments with informant-based functional assessments [17]. Furthermore, the European Prevention
of Alzheimer’s Dementia (EPAD) group has implemented a comprehensive battery of cognitive tests that
assess several cognitive domains [18]. Many of the tests
in the EPAD battery are widely used verbal or paper and
pencil tests, while others are novel computer-based tasks
that are intended to measure cognitive changes associated with specific cortical regions known to be differentially affected by AD pathology [18]. Although there is
evidence demonstrating that these composite scores
have good sensitivity to clinical change [12–16], it is unclear whether these particular composite scores correlate
with autopsy-confirmed AD pathology.
Other groups have shown that cognitive composite
scores correlate well with AD pathology among individuals with no cognitive impairment (NCI) who had not
progressed to MCI or AD at the time of death [19–21].
Boyle et al. [19] showed that higher levels of both amyloid and tau load were associated with longitudinal decreases in global cognition after adjusting for age, sex,
and education. Riley et al. [20] revealed that NCI individuals with a NIA-Reagan diagnosis of intermediate or
high likelihood of AD had significantly greater antemortem cognitive decline relative to those with the no or
low likelihood diagnoses. Monsell et al. [21] reported
that NCI individuals with high levels of AD pathology
had significantly greater decline on a composite score of
attention/working memory when compared with NCI
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individuals with no evidence of AD pathology. Together,
these studies provide evidence that elderly people that
died with an antemortem clinical diagnosis of NCI but
who displayed extensive AD pathology on brain neuropathological evaluation postmortem show a significant
decline on a composite memory score.
Although it appears that cognitive composite score
changes correlate with the presence of AD-related pathology among aged individuals who are cognitively stable,
whether similar associations exist in individuals that progress to MCI or AD remains to be investigated. Since
AD prevention trials are likely to enroll individuals who
progress to MCI during the course of the study, understanding the nature of cognitive trajectories among progressors and nonprogressors is needed. Therefore, the
aim of this study was to define the relationship between
longitudinal changes on a cognitive composite score and
postmortem plaque and neurofibrillary tangle (NFT)
pathology among NCI individuals who did and did not
progress to MCI and AD.

Methods
The data examined were derived from 192 older deceased and autopsied persons who were classified as
NCI at their initial clinical evaluation. At the last testing
within 12 months prior to death, 105 of these individuals
remained NCI while the remaining 87 progressed to
MCI (n = 40) or AD (n = 47) (Table 1). Among those
who progressed to MCI, 13 were classified as amnestic
and 27 were classified as nonamnestic. Previous work by
our group has shown that plaque and tangle pathology
does not differ significantly between amnestic and nonamnestic MCI subjects in this cohort [22]. These individuals were participants in the Rush Religious Order
Study (RROS) [23, 24], had no coexisting clinical or
neurological conditions judged to contribute to cognitive
impairment at their last clinical evaluation [23, 24],
agreed to annual clinical evaluations, and signed an informed consent and an Anatomic Gift Act donating
their brains at the time of death. Data from these subjects have been used in numerous clinical pathological
studies supported by our ongoing NIA program project
grant entitled the “Neurobiology of Mild Cognitive Impairment in the Elderly” (PO1AG14449). At the time of
these studies, individuals were chosen from all available
RROS participants that came to autopsy during a rolling
admission [23]. In addition, those taking anticholinesterases or medication for depression were also excluded.
The Human Investigation Committee of Rush University
Medical Center approved this study.
Clinical evaluation

Each of the participants underwent a uniform, structured, and clinical evaluation performed by a neurologist
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Table 1 Demographic, cognitive, and postmortem data by progression status
Progressors

Nonprogressors

p value

Effect size

n

87

105

NA

NA

Gender (male/female), n

27/60

54/51

< 0.001

NA

APOE e4 (carrier/noncarrier), n

25/62

18/87

0.06

NA

Age at baseline (years)

78.95 ± 5.93

76.40 ± 6.16

< 0.001

0.42

Age at death (years)

87.84 ± 5.67

84.48 ± 5.61

< 0.001

0.60

Education (years)

18.31 ± 3.22

18.20 ± 3.57

0.82

0.03

MMSE at baseline

28.28 ± 1.78

28.68 ± 1.39

0.08

0.25

MMSE proximate to autopsy

21.92 ± 6.61

28.30 ± 1.29

< 0.001

1.34

Length of follow-up (years)

7.65 ± 3.72

7.23 ± 4.75

0.50

0.10

Baseline composite score

67.24 ± 6.85

69.08 ± 7.37

0.08

0.26

Interval between last
clinic visit and autopsy (months)

0.69 ± 0.55

0.68 ± 0.57

0.95

0.02

Postmortem interval (h)

6.95 ± 5.15

7.11 ± 6.95

0.85

0.03

Brain weight at autopsy (g)

1165.97 ± 131.11

1224.61 ± 142.93

< 0.001

0.43

Values are shown as mean ± standard deviation unless otherwise indicated
Effect size = Cohen’s d
MMSE Mini Mental State Examination, NA not applicable

and a trained neuropsychological test technician [23,
25]. Medications used by the subjects within the previous 14 days of the examination were reviewed and classified. A neurologist reviewed the medical history,
medication use, neurologic examination, results of cognitive performance testing, and the neuropsychologist’s
opinion of cognitive impairment and dementia. Each
participant was evaluated in their home, emphasizing
findings deemed clinically relevant. Clinical diagnostic
classification was performed as described previously
[23, 25]. At the time of death, individuals with a clinical diagnosis of MCI or AD were classified as progressors and those classified as NCI were categorized
as nonprogressors. Progression to MCI or AD was
determined by performance on neuropsychological
tests as well as a clinical examination by a neurologist. Based on these cognitive and clinical data, a
diagnostic algorithm was used to determine the clinical status of each participant [26].
Tissue preparation and neuropathological diagnosis

Brain accruement and processing was as described previously [25, 27]. Briefly, each brain was cut into 1-cm thick
coronal slabs using a brain slice apparatus and hemisected.
One hemisphere was immersion fixed in 4% paraformaldehyde (24–72 h) and cryoprotected (10% glycerol and 2%
dimethyl sulfoxide in phosphate-buffered solution) until
processing for immunohistochemistry.
Diagnostic blocks (mid-frontal, superior temporal, entorhinal cortex, hippocampus, inferior parietal cortex, basal
ganglia, thalamus, and substantia nigra) from the opposite
hemisphere were paraffin embedded and cut at 6 μm.
Examination for cerebral infarctions was conducted as

described previously [28]. Bielschowsky silver stain was
used to visualize neuritic plaques (NPs), diffuse plaques
(DPs), and NFTs. Sections were also immunostained for
amyloid beta (Aβ) using antibody M0872 (1:100; Dako,
CA) raised against Aβ1–40 and Aβ1–42. Paired helical filament tau (AT8; 1:800, Covance) immunohistochemistry
was also used to label NFTs. Neuropathological diagnoses
were determined according to Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) [29] and Braak
staging [30] as recommended by the NIA-Reagan criteria
[31]. Exclusion criteria included mixed dementias, Parkinson’s disease, frontotemporal dementia, argyrophilic grain
disease, vascular dementia, hippocampal sclerosis,
stroke, and Lewy body disease. Lewy bodies in the
substantia nigra, entorhinal, cingulate, midfrontal,
middle temporal, and inferior parietal cortex were detected using α-synuclein immunohistochemistry as previously described [32] and scored semiquantitatively
according to the severity and anatomical distribution,
separating brainstem predominant, limbic/transitional,
and diffuse neocortical types, depending on the anatomical distribution of the α-synuclein positivity [33,
34]. A board-certified neuropathologist or trained technician, blinded to clinical diagnosis, counted the number of NPs and DPs revealed by Bielschowsky silver
stain and Tau immunohistochemistry using the phosphorylated paired helical filament tau AT8 marker for
NFTs, respectively, in one square millimeter area (100×
magnification) per cortical region as reported previously [35, 36]. NP and NFT counts used in this study
were a summation of counts from the entorhinal cortex, CA1 hippocampus, midfrontal cortex, midtemporal
cortex, and inferior parietal cortex.

Malek-Ahmadi et al. Alzheimer's Research & Therapy (2018) 10:90

Cognitive composite score

The composite score was comprised of eight cognitive
tests that included the CERAD Word List Delayed Recall, WMS-R Logical Memory (delayed recall), Category
Fluency (Fruits and Animals), Symbol Digit Modalities
Test, Ravens Progressive Matrices (9-item), Judgment of
Line Orientation (15-item), MMSE Orientation to Time,
and MMSE Orientation to Place. The composite score
used in this study is based on that of Langbaum et al.
[12], but was refined to reflect the selection of tests being used in on-going AD prevention trials [37, 38]. The
tests that comprise this composite score are the same, or
are analogous to, those used in other composite scores
[12–14]. A list of the individual tests used to create the
current composite score and others is shown in Table 2.
The tests that form the composite score are intended
to assess change in the cognitive domains of episodic
memory (CERAD Word List Delayed Recall, WMS-R
Logical Memory), attention/processing speed (Symbol
Digit Modalities Test), executive function (Ravens
Progressive Matrices), language (Category Fluency),
visuospatial function (Judgment of Line Orientation),
and orientation (MMSE Orientation to Time, and
MMSE Orientation to Place). Several of these tests
have been used in the formation of other composite
scores [13, 14, 17]. Another score utilizes the Repeatable Battery for the Assessment of Neuropsychological
Stats (RBANS), which includes List Learning and
Story Memory tests to assess episodic memory as well
as other tests that assess attention (Coding and Digit
Span), language (Picture Naming and Semantic Fluency), and visuospatial function (Figure Copy and
Line Orientation) [18].
Individual raw scores for each test were standardized to a 0 to 1 scale by subtracting the minimum
possible score for a test from the raw score and then
dividing by the difference of the maximum and minimum possible scores:

Page 4 of 12

Standardized score ¼ ðraw score  minimum possible scoreÞ=
ðmaximum possible score  minimum possible scoreÞ

Since the Category Fluency test does not have an
established maximum score, two standard deviations
above the mean was used as the maximum. This method
has been applied previously for a similar cognitive composite score [12]. No adjustments for directionality were
needed since lower scores are indicative of decreased
performance for all tests. The standardized scores for
each test were then summed and divided by eight (the
number of tests) to obtain an unweighted average. Finally, for scaling purposes, standardized scores were
multiplied by 100.
An annualized rate of change for the composite score
was calculated by subtracting the score at the last visit
from the baseline score and then dividing by the difference in age between the two visits.
Annualized change ¼ ðscore at last visit  score at baselineÞ=
ðage at last visit  age at baselineÞ

Statistical analysis

Between-group frequency differences for categorical variables were analyzed using the Chi-square test while
between-group differences for continuous variables were
compared with a two-sample t test. Annualized cognitive
composite score change differences for CERAD neuropathological diagnosis and Braak stage were evaluated
using a one-way analysis of variance (ANOVA). Braak
stage was divided into three groups (0 to II, III, and IV
to V) to maintain adequate group sizes for the ANOVA.
This Braak stage grouping scheme also allowed for the
transentorhinal stage (I and II) of NFT deposition to be
differentiated from the intermediate limbic stage (III)
[28]. Braak stage III was grouped independently since
the transition from Braak stage III to IV is thought to
coincide with the transition from normal cognition to

Table 2 Composite score comparison between studies
Publication

Composite score components

Current study

CERAD Word List Delayed Recall, WMS-R Logical Memory (Delayed Recall), Category Fluency, Symbol Digit Modalities Test,
Ravens Progressive Matrices (9-Item), Judgment of Line Orientation (15-Item), MMSE Orientation to Time, MMSE Orientation
to Place.

Langbaum et al. [12]

East Boston Memory Test (Immediate Recall), WMS-R Logical Memory (Delayed Recall), Boston Naming Test (15-Item),
Category Fluency, MMSE Orientation to Time, Ravens Progressive Matrices (9-Item), Symbol Digit Modalities Test

Donohue et al. [13]

Free and Cued Selective Reminding Test (Total Score), MMSE (Total Score), WMS-R Logical Memory (Delayed Recall), WAIS-R
Digit Symbol Substitution

Coley et al. [14]

MMSE Orientation to Time, MMSE Orientation to Place, Free and Cued Selective Reminding Test (Total Score), Category
Fluency, Trail-Making Test Part B

Jutten et al. [17]

ADAS-Cog Word Recall, ADAS-Cog Word Recognition, ADAS-Cog Orientation, Digit Span Backward, Controlled Oral Word
Association Test, Category Fluency, Digit Symbol Substitution Test

Ritchie et al. [18]

RBANS List Learning, RBANS Story Memory, RBANS Figure Copy, RBANS Line Orientation, RBANS Picture Naming, RBANS
Semantic Fluency, RBANS Coding, RBANS Digit Span, NIH Examiner Toolbox Dot Counting, NIH Examiner Toolbox Paired
Associate Learning, NIH Examiner Toolbox Eriksen Flanker Task, Four Mountains Task
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dementia [39]. Stages IV and V were grouped together
as none of the subjects were classified in stage VI. The
Tukey HSD test was used for post-hoc group-wise
comparisons.
Annualized composite score change was also analyzed
when the cases were grouped based on pathology severity as measured by CERAD criteria and Braak stage. The
low CERAD group consisted of those with the no AD
classification, while possible, probable, and definite AD
were classified as high CERAD. Low Braak stage consisted of individuals ranging from 0 to II and high Braak
stage included individuals ranging from III to V.
In addition, mixed-model repeated measure (MMRM)
analyses were used to examine change from baseline differences on the composite score between high and low
pathology groups. In these analyses, time was treated as
a categorical variable and data were restricted to the first
six visits for each subject (baseline plus 5 years of
follow-up). This follow-up length was selected to approximate the duration of current AD prevention trials
[2, 37, 38]. Unstructured covariance structure was
attempted for all models. In the event that the models
did not converge, autoregressive order 1 (AR(1))
followed by variance component (VC) structures were
used. Kenward-Roger approximation for degrees of freedom was used for all models. The MMRM models included fixed-effects for visit, age at baseline, gender,
education, APOE ε4 carrier status, baseline composite
score, pathology group, and visit by pathology group
interaction. The primary outcome for each analysis was
the least-squares difference of composite score change
between the low and high pathology groups. Separate
MMRM models were carried out to compare change
from baseline differences in high versus low CERAD and
high versus low Braak stage. A third MMRM model was
carried out which grouped the participants based on
both their CERAD and Braak stage status (high CERAD/
high Braak, low CERAD/low Braak, and intermediate
(high CERAD/low Braak and low CERAD/high Braak)).
The t tests and ANOVA were carried out using
SYSTAT 13.1 (SYSTAT Software Inc., San Jose, CA).
SAS Enterprise Guide 6.1 (SAS Institute, Cary, NC) was
used for the MMRM analyses. Statistical significance
was set at p ≤ 0.05.

also significantly older at their time of death relative to
nonprogressors (p < 0.001); however, the two groups did
not differ on years of education (p = 0.82), baseline Mini
Mental State Examination (MMSE) (p = 0.08), length of
follow-up (p = 0.50), or baseline composite score (p =
0.08). MMSE proximate to death was significantly lower
for progressors (p < 0.001). The interval between the last
clinic visit and death and postmortem interval were not
significantly different (p = 0.95 and p = 0.85, respectively). Progressors had significantly lower brain weight at
autopsy compared with nonprogressors (p < 0.001).
For the neuropathological variables (Table 3), CERAD
neuropathological diagnosis prevalence of the no AD
classification was significantly higher among nonprogressors (p < 0.001). Braak stage V was more prevalent
among progressors than nonprogressors (p = 0.01).

Results

Braak stage

Demographic and postmortem characterization

Demographic, cognitive, and postmortem characteristics
of the study sample are shown in Table 1. Females were
more likely to progress to MCI/AD than males (p <
0.001). APOE ε4 status was not associated with disease
progression (p = 0.06). Individuals who progressed to
MCI or AD were approximately 2.5 years older than
nonprogressors at baseline (p < 0.001). Progressors were

Cognitive composite score and neuropathology
associations

Annualized composite score change between the CERAD
classifications was significantly different (p < 0.001), with
the no AD group showing a significantly slower rate of
change relative to the probable AD (p = 0.01) and definite
AD groups (p < 0.001) (Fig. 1). All other CERAD
group-wise comparisons were not significantly different.
For Braak stage, the 0 to II group showed a significantly
slower annualized composite score change relative to the
III (p = 0.01) and IV to V (p < 0.001) groups (Fig. 2). The
Braak stage III and IV to V groups were not significantly
different (p = 0.99).
Significant differences for the annualized cognitive
composite score change was noted for both the CERAD
and Braak stage groupings (both p < 0.001) with medium
effect sizes (CERAD d = 0.56; Braak stage d = 0.55). Data
for these analyses are shown in Table 4.
Table 3 Neuropathological data by progression status
Progressors (n) Nonprogressors (n) p value
CERAD neuropathological
diagnosis
No AD

< 0.001
18

41

Possible AD

6

14

Probable AD

39

38

Definite AD

24

12
0.01

0

0

2

I

9

19

II

7

17

III

24

31

IV

23

31

V

24

5

AD Alzheimer’s disease
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Table 4 Annualized cognitive composite score change differences
for high and low pathology groupings
CERAD

Braak stage

High

Low

p value

Effect size

< 0.001

0.56

< 0.001

0.55

−1.59 ± 2.40

−0.26 ± 2.36

n = 133

n = 59

−1.57 ± 2.23

−0.19 ± 2.75

n = 138

n = 54

Values are shown as mean ± standard deviation
Effect size = Cohen’s d

Fig. 1 Annualized composite score change by CERAD neuropathological
diagnosis. Boxes represent the mean and error bars are standard
deviation. No Alzheimer’s disease (AD) vs probable AD, p = 0.01;
no AD vs definite AD, p < 0.001; all other group-wise comparisons were
not significantly different

The MMRM analysis for the CERAD grouping
showed that the composite score change from baseline difference between the high and low CERAD
groups was statistically significant (Δ = −2.74, 95%
confidence interval (CI) −5.01 to −0.47; p = 0.02), with
the high CERAD group showing a significantly greater
change from baseline (Fig. 3). For Braak stage, the
composite score change from baseline difference between the low and high groups was not statistically
significant (Δ = −0.69, 95% CI −3.03 to 1.66; p = 0.56).
Although the high/low Braak stage group difference
was not statistically significant, independently, these
groups both showed a statistically significant decline

from baseline (high Braak: Δ = −3.99, 95% CI −5.25 to
−2.74; p < 0.001; low Braak: Δ = −3.30, 95% CI −5.38
to −1.23; p = 0.002) (Fig. 4).
For the three-group analysis, the group sizes were as
follows: high CERAD/high Braak, n = 56; intermediate,
n = 53; low CERAD/low Braak, n = 83. The composite
score change from baseline difference between the high
CERAD/high Braak and the low CERAD/low Braak was
not statistically significant (Δ = −0.78, 95% CI −3.81 to
2.24; p = 0.61). Further examination of the low CERAD/
low Braak group found that eight individuals who progressed had composite score change from baseline estimates ranging from −2.15 to −21.70 (mean ± SD, −7.28
± 6.61), which could explain the nonsignificant difference with the high CERAD/high Braak group. The intermediate group showed a significantly greater change
from baseline than the low CERAD/low Braak group (Δ
= 3.85, 95% CI 0.55–7.15; p = 0.02). Composite score decline for the high CERAD/high Braak group was significantly greater than that of the intermediate group (Δ =
−4.63, 95% CI −7.09 to −1.58; p = 0.002) (Fig. 5).
Within-group and between-group change from baseline
estimates for each MMRM model are shown in Table 5.
AR(1) covariance structure was used for all MMRM
models due to a lack of convergence when using unstructured covariance.

Post-hoc MMRM analyses

Fig. 2 Annualized composite score change by Braak stage. Boxes
represent the mean and error bars are standard deviation. 0 to II vs
III, p = 0.01; 0 to II vs IV to V, p < 0.001; III vs IV to V, p = 0.99

When change from baseline differences for APOE ε4 carrier status were assessed, ε4 carriers were found to have
significantly greater change from baseline relative to ε4
noncarriers (Δ = −3.15, 95% CI −5.63 to −0.66; p = 0.01).
For progression status, progressors displayed significantly
greater change from baseline than nonprogressors (Δ =
−7.51, 95% CI −9.48 to −5.53; p < 0.001). MMRM models
restricted to nonprogressors were performed to determine
the effect of pathology group differences on the composite
score. For high/low CERAD groups, the difference in
change from baseline was not statistically significant (Δ =
−1.17, 95% CI −3.39 to 1.05; p = 0.30). The difference for
the high/low Braak groups was also not significant (Δ =
0.52, 95% CI −1.78 to 2.82; p = 0.66).
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Fig. 3 Least squares composite score estimates for high and low CERAD groups. Group difference in change from baseline was statistically
significant (Δ = −2.74, 95% CI −5.01 to −0.47; p = 0.02). Error bars indicate standard error

Z score standardization of the composite score

An additional analysis was performed using a z score
transformation to create the composite score. The individual cognitive tests at each visit were standardized to
the mean and standard deviation of their baseline values,
which generated a z score for each raw test value. The z
scores for each individual at each visit were summed
and divided by eight to create a composite z score.
Change from baseline analyses for the composite z score
were conducted similar to the previous MMRM analyses. The high CERAD group showed worse performance relative to the low CERAD group on the composite
z score, but this difference was not statistically significant (Δ = −0.16, 95% CI −0.33 to 0.01; p = 0.06). The
composite z score difference for the high and low Braak
stage groups was also not significant (Δ = −0.03, 95% CI
−0.20 to 0.14; p = 0.74). For the three-group analysis, the
composite z score results were similar to the previous
three-group analysis where the high CERAD/Braak
group had significantly greater decline than the
intermediate group (Δ = −0.33, 95% CI −0.50 to −0.15;
p < 0.001), but not the low CERAD/Braak group (Δ =
0.00, 95% CI −0.23 to 0.22; p = 0.98). Similar to the previous analysis, the intermediate group had significantly
better performance than the low CERAD/Braak group
(Δ = 0.32, 95% CI 0.08–0.57; p = 0.01).

Discussion
The results of this study demonstrate a significant association between AD-related amyloid and tau pathology
and a cognitive composite score similar to those used in
on-going AD prevention trials [12–14, 38, 39]. In
addition, these findings serve to establish a relatively robust association between a cognitive outcome and AD

pathology. Our results also provide empirical support for
the use of cognitive composite scores as a primary outcome for AD prevention trials. Although many of the
current AD therapies in clinical trials are focused primarily on amyloid reduction [40], the continued development of tau-directed treatments [41] will require that
cognitive composite scores correlate well with both AD
lesions. These results are important in light of the Food
and Drug Administration’s (FDA) revised guidance for
drug development in early AD [9], which indicates that
approval for a new treatment could be obtained based
on a “persuasive effect” on a cognitive outcome. However, the guidelines emphasize that a study sponsor must
demonstrate that cognitive function is related to
underlying disease pathology in a broader clinical
context (certainty of diagnosis and future clinical
course) [9]. Previous studies have shown that cognitive trajectories in cognitively stable individuals are
impacted by the severity of AD pathology [19–21].
Here we found the same association in a mixed sample of progressors and nonprogressors. Since AD prevention trials are likely to include individuals who
will progress to MCI during the course of the trial,
including these subjects in our analysis provides a
more accurate estimate of cognitive trajectories in the
context of an AD prevention trial.
Since other currently used composite scores [13, 14, 17,
18] are comprised of the same, or similar, cognitive subtests to those employed here, it is likely that their association with AD pathology would be comparable with our
composite score. Although the FDA’s revised guidance for
early AD drug development [9] provides greater latitude
in the use of cognitive outcomes for efficacy analyses,
there is still a need to demonstrate that observed cognitive
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Fig. 4 Least squares composite score estimates for high and low Braak stage. Group difference in change from baseline was not statistically
significant (Δ = −0.69, 95% CI −3.03 to 1.66; p = 0.56). Within-group change from baseline was statistically significant for both groups (high Braak:
Δ = −3.99, 95% CI −5.25 to −2.74; p < 0.001; low Braak: Δ = −3.30, 95% CI −5.38 to −1.23; p = 0.002). Error bars indicate standard error

changes are associated with underlying disease pathology
as suggested by the current study.
This present study also lends support to the requirement that potential subjects display positive amyloid
scans to meet inclusion criteria in AD prevention trials.
Since AD prevention trial inclusion criteria include clinically asymptomatic individuals with significant AD
pathology who are at a higher risk for the development
of cognitive symptoms, it is these individuals in which
preclinical intervention(s) may significantly delay or halt
the onset of clinical decline. The results derived from

the CERAD high/low grouping show that individuals
with high plaque load had significantly greater annualized declines on the composite score relative to those
with low plaque load. In addition, the medium effect size
(d = 0.56) indicates clinical relevance for this difference.
Amyloid imaging evidence has shown that decreased
performance in several different cognitive domains is associated with greater amyloid load in cortical regions associated with AD (e.g., precuneus, anterior cingulate,
posterior cingulate, temporal cortex, pre-frontal cortex, etc.) [42]. Others have shown that increased

Fig. 5 Least squares composite score estimates for high, intermediate, and low pathology groups. Group differences in change from baseline
were statistically significant for intermediate vs. low (p = 0.01) and intermediate vs high (p < 0.001), but not for high vs. low (p = 0.61). Error bars
indicate standard error
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Table 5 MMRM-estimated cognitive composite score change from baseline results
Δ from baseline

p value

Δ from low group

p value

Low CERAD

− 1.80 (−3.79, 0.19)

0.08

NA

NA

High CERAD

−4.54 (−5.80, −3.28)

< 0.001

−2.74 (−5.01, − 0.47)

0.02

Low Braak

−3.30 (−5.38, −1.23)

0.002

NA

NA

High Braak

−3.99 (−5.25, −2.74)

< 0.001

−0.69 (−3.03, 1.66)

0.56

Low CERAD/low Braak

−4.34 (−7.09, −1.58)

0.002

NA

NA

Intermediate

−0.49 (−2.52, 1.54)

0.64

3.85 (0.55, 7.15)

0.02

High CERAD/high Braak

−5.12 (−6.48, −3.76)

< 0.001

−0.78 (−3.81, 2.24)

0.61

Values are shown as least-squares mean (95% confidence interval)
NA not applicable

plaque and NFT pathology in the entorhinal cortex,
CA1, and subiculum is associated with worse antemortem memory performance [43]. Our findings are
similar to these domain- and region-specific cognition
and pathology associations.
MMRM analysis did not reveal significant differences
in composite score trajectory between the low and high
Braak groups (p = 0.56), indicating that the groups had
similar rates of decline (Fig. 4). In addition, the MMRM
analysis of the low and high CERAD groups showed that
the high CERAD group had a significantly greater
change from baseline relative to the low CERAD group
(p < 0.001). Furthermore, an additional MMRM analysis
revealed that individuals in the high CERAD and high
Braak stage groups exhibited greater change from baseline relative to the intermediate pathology group. The
lack of significance between the high CERAD/high Braak
and the low CERAD/low Braak groups is surprising, but
may be driven by the inclusion of eight progressors in
the low CERAD/low Braak cohort that showed significant cognitive decline. Overall, these results suggest that
increased plaque burden drives the observed change in
the composite score, which contrasts with other studies
showing that both NFTs and NPs are associated with
cognitive decline [44, 45]. A study by our group found a
lack of association between NFT load and cognition in a
cross-sectional analysis [46], but in a subsequent longitudinal analysis we found that the interaction of higher
Braak stage, older age, and positive APOE ε4 status were
associated with declines in episodic memory and executive function in NCI older adults [47]. Furthermore, we
previously found that decreased cognitive performance
in NCI subjects in a cross-sectional study was associated
with NP load and not DP load [48].
The finding that the intermediate pathology group
performed significantly better than the low CERAD/low
Braak stage group in the three-group MMRM analysis is
curious. A possible explanation might be that cognitive
reserve mechanisms allowed the intermediate group to
maintain cognitive function in the presence of plaque or
tangle pathology [46, 49]. However, of the 53 subjects in

the intermediate group, 29 displayed high Braak pathology raising the possibility that these may be cases of
neurofibrillary tangle predominant dementia (NFTPD)
in which the APOE ε4 allele is less prevalent and cognitive impairment is less severe relative to sporadic AD
[50, 51]. Only three of the 29 high Braak subjects were
APOE ε4 carriers and this group did not show a significant decline from baseline. The lack of cognitive composite score decline in the high Braak group may also
suggest the presence of primary age-related tauopathy
(PART), which is characterized by the presence of NFT
pathology with no or minimal amyloid plaque deposits
and is associated with a lack of cognitive decline and
low APOE ε4 prevalence [52]. Since these cases displayed both plaque and tangle pathology, they do not
meet the criteria for PART.
Another important issue raised by this study is the
relative discordance of neuropathological and clinical
status and its impact on the interpretation of composite
score differences. Here we found that the probable AD
CERAD diagnosis and advanced Braak scores were relatively equal between progressors and nonprogressors.
Heterogeneity of AD neuropathology among NCI individuals has been reported previously by our group in the
population examined here [46–48], which may be related to the observation that some of the CERAD diagnostic groups were not significantly different on the
annualized composite score change. When high and low
pathology status was considered, annualized change was
significantly lower among the high CERAD and high
Braak stage groups with effect sizes that also indicated
clinical relevance. Although it is unclear whether these
effect sizes relate to treatment efficacy, they suggest that
significant treatment effects could be observed if
disease-modifying therapies are initiated early.
Composite scores have been used as clinical trial endpoints in other therapeutic areas [53], allowing for multiple components of a particular outcome to be
measured in a single index. Since the clinical presentation of MCI and AD can differ in terms of which cognitive domains show the earliest decline, cognitive
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composite scores allow for these changes to be observed
while not requiring additional statistical power if each
cognitive test were treated as separate outcomes. Moreover, how components of a composite score are
weighted is also an important issue [54, 55]. Donohue
and colleagues [13] commented that differing weights
among the components of a cognitive composite score
are not easily attained since there is no a priori evidence
of how a weighting scheme relates to a treatment response. In addition, implementing a fixed weighting
scheme assumes a degree of homogeneity in the clinical
presentation and course of decline in cognitive domains.
Since decline in nonmemory domains may not occur at
the same frequency or at the same trajectory between individuals, giving equal weight to the components of a
composite score might allow for cognitive decline to be
measured more accurately in the presence of heterogeneous clinical presentations. Others have shown relative
improvement in treatment-effect detection using linear
weights in a cognitive composite score [55]; however,
the use of linear weighting may produce only marginal
gains in statistical power [55].
Another challenge in the interpretation of the current
findings is the follow-up timeframe. Although we restricted the follow-up length to 5 years to approximate
that of AD prevention trials, it is reasonable to expect
that many individuals may develop clinical symptoms of
MCI/AD after this timeframe. Therefore, the prognostic
value of these results may be limited. In this study, the
composite score differences were not clear until year 4,
and it is likely that these differences were driven by progressors with high pathology. An additional limitation is
the relatively small number of APOE ε4 carriers, particularly homozygous individuals, which may affect the associations reported here. Future studies with a greater
balance of APOE ε4 carriers and noncarriers will extend
these results. The subjects in this study were from a
community-based group of highly educated retired
clergy who had excellent healthcare and nutrition and
were used in multiple clinical pathological [56] and epidemiological investigations [35]. Individuals who volunteer may introduce bias by decreasing pathology, but
this is partially mitigated by high follow-up and autopsy
rates of the RROS [27]. The findings presented here may
be limited to a less heterogeneous population since the
individuals examined were virtually absent of vascular or
other comorbid neuropathology. Since vascular lesions
and other neuropathologies frequently occur in the presence of classic AD pathology, this cohort is more representative of those individuals that would be chosen for
an AD clinical prevention trial.
Study strengths include uniform premortem clinical
and postmortem pathological evaluation and that the
final pathologic classification was performed without
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knowledge of the clinical evaluation. An additional
strength is that our results are easily translatable to clinical trials since the MMRM approach is often used to
analyze the primary outcome of AD clinical trials [57–
63]. In this study, the selection of covariates is similar to
that used in the efficacy analyses of clinical AD trials
[57–63]. Furthermore, the cognitive composite score
used in the present investigation is similar to composites
currently being used in on-going AD prevention trials
[12–14, 37, 38], which adds to the generalizability of our
findings.

Conclusion
The results of this study are prescient given that cognitive composite scores are being utilized as primary outcomes in AD prevention trials. The findings presented
here establish that cognitive composite score performance correlates well with AD pathology in a preclinical
context. By showing that a clinical outcome is associated
with treatment targets of on-going AD prevention trials,
these results may provide additional support for prevention trials that demonstrate beneficial treatment effects.
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